Kadmon Holdings is a biopharmaceutical company. Co.'s clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. Co. is developing oral small molecule inhibitors of Rho-associated coiled-coil kinase (ROCK) to treat immune and fibrotic diseases. Co.'s main product candidate, Belumosudil (KD025), is an orally administered, selective small molecule inhibitor of ROCK 2. Belumosudil is for the treatment of patients with chronic graft-versus-host disease (cGVHD). In addition to cGVHD, Co. is developing belumosudil in for the treatment of systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis and vascular damage. The KDMN average annual return since 2016 is shown above.
The Average Annual Return on the KDMN average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether KDMN average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KDMN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|